Evidence map›Paper›PMID 36145296›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Assembly of Celastrol to Zeolitic Imidazolate Framework-8 by Coordination as a Novel Drug Delivery Strategy for Cancer Therapy.

Na Wang, Yifan Li, Fei He, Susu Liu, Yuan Liu, Jinting Peng, Jiahui Liu, Changyuan Yu, Shihui Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Multifunctional FePharmaceutics · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Na WangCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Yifan LiCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Fei HeCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Susu LiuCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Yuan LiuCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Jinting PengDepartment of Gynecology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, China.
Jiahui LiuAnalytical Instrumentation Center, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
Changyuan YuCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Shihui WangCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.ORCID 0000-0001-6130-0451
Beijing University of Chemical Technology · CNPeking University · CNShenzhen Pingle Orthopedic Hospital · CN

Funding

National Key Research and Development Project 218YFA0903000National Natural Science Foundation of China 21606013National Natural Science Foundation of China 82174531Shenzhen Science and Technology Project JCYJ20180507183842516
6 · The paper itself

Abstract

Celastrol (Cel), a compound derived from traditional Chinese medicine

Indexed as

anticancerassemblecelastroldrug deliverynanomaterial

Identifiers

PMID36145296
PMCPMC9504028
OpenAlexW4293769465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.